Ken Griffin’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $95K | Sell |
24,600
-1,600
| -6% | -$6.3K | ﹤0.01% | 12056 |
|
|
2025
Q4 | $103K | Sell |
26,200
-3,900
| -13% | -$17.3K | ﹤0.01% | 11613 |
|
|
2025
Q3 | $141K | Buy |
30,100
+9,200
| +44% | +$33.3K | ﹤0.01% | 11582 |
|
|
2025
Q2 | $65K | Buy |
20,900
+8,000
| +62% | +$25.8K | ﹤0.01% | 11636 |
|
|
2025
Q1 | $43.6K | Buy |
12,900
+6,900
| +115% | +$32.2K | ﹤0.01% | 12443 |
|
|
2024
Q4 | $34K | Buy |
6,000
+400
| +7% | +$2.58K | ﹤0.01% | 12756 |
|
|
2024
Q3 | $32.8K | Sell |
5,600
-6,900
| -55% | -$50.2K | ﹤0.01% | 12352 |
|
|
2024
Q2 | $98.9K | Buy |
12,500
+1,700
| +16% | +$14.3K | ﹤0.01% | 10931 |
|
|
2024
Q1 | $101K | Buy |
10,800
+5,100
| +89% | +$43.1K | ﹤0.01% | 11354 |
|
|
2023
Q4 | $48.1K | Sell |
5,700
-700
| -11% | -$5.08K | ﹤0.01% | 11816 |
|
|
2023
Q3 | $49.6K | Sell |
6,400
-9,500
| -60% | -$86.7K | ﹤0.01% | 11771 |
|
|
2023
Q2 | $182K | Sell |
15,900
-300
| -2% | -$3.1K | ﹤0.01% | 10038 |
|
|
2023
Q1 | $125K | Sell |
16,200
-1,400
| -8% | -$11.1K | ﹤0.01% | 10941 |
|
|
2022
Q4 | $107K | Sell |
17,600
-24,300
| -58% | -$138K | ﹤0.01% | 11119 |
|
|
2022
Q3 | $248K | Sell |
41,900
-4,800
| -10% | -$30.7K | ﹤0.01% | 9988 |
|
|
2022
Q2 | $276K | Sell |
46,700
-46,000
| -50% | -$311K | ﹤0.01% | 9980 |
|
|
2022
Q1 | $706K | Sell |
92,700
-1,200
| -1% | -$5.35K | ﹤0.01% | 8554 |
|
|
2021
Q4 | $254K | Buy |
93,900
+21,600
| +30% | +$73.7K | ﹤0.01% | 11318 |
|
|
2021
Q3 | $190K | Sell |
72,300
-18,200
| -20% | -$59.1K | ﹤0.01% | 12061 |
|
|
2021
Q2 | $374K | Buy |
90,500
+39,500
| +77% | +$179K | ﹤0.01% | 10738 |
|
|
2021
Q1 | $240K | Buy |
51,000
+33,300
| +188% | +$227K | ﹤0.01% | 11332 |
|
|
2020
Q4 | $127K | Buy |
17,700
+6,500
| +58% | +$62.5K | ﹤0.01% | 10057 |
|
|
2020
Q3 | $120K | Sell |
11,200
-1,000
| -8% | -$11.7K | ﹤0.01% | 9165 |
|
|
2020
Q2 | $154K | Sell |
12,200
-2,000
| -14% | -$23.3K | ﹤0.01% | 8726 |
|
|
2020
Q1 | $130K | Buy |
14,200
+1,900
| +15% | +$21.8K | ﹤0.01% | 8417 |
|
|
2019
Q4 | $172K | Sell |
12,300
-3,500
| -22% | -$50.9K | ﹤0.01% | 8288 |
|
|
2019
Q3 | $272K | Sell |
15,800
-600
| -4% | -$12.6K | ﹤0.01% | 7700 |
|
|
2019
Q2 | $446K | Sell |
16,400
-200
| -1% | -$4.58K | ﹤0.01% | 6999 |
|
|
2019
Q1 | $318K | Buy |
+16,600
| New | +$216K | ﹤0.01% | 7529 |
|
|
2018
Q4 | – | Sell |
-16,200
| Closed | -$307K | – | 9827 |
|
|
2018
Q3 | $307K | Buy |
+16,200
| New | +$311K | ﹤0.01% | 7520 |
|
Other funds holding VYGR
AC
VPC
VCM
OM
EAM
Ken Griffin's VYGR Position: Q1 2026 in Review
Ken Griffin reduced its Voyager Therapeutics (VYGR) stake by 34% in Q1 2026, selling an estimated $756K and leaving 364,664 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #6863.
Ken Griffin first reported a position in VYGR in Q3 2017 and has held it in 32 quarters since. The position peaked at $8.95M in Q3 2020. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.
- Ken Griffin held 364,664 shares of Voyager Therapeutics worth $1.41M as of Q1 2026.
- Ken Griffin sold 191,982 Voyager Therapeutics shares in Q1 2026, an estimated $756K.
- Voyager Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6863 holding.
- Ken Griffin first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 32 quarters since.
- Ken Griffin's Voyager Therapeutics position peaked at $8.95M in Q3 2020.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.